logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma's TH-302 Receives EC's Orphan Drug Designation

Threshold Pharmaceuticals, Inc. (THLD) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.

Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Automotive startup Divergent 3D said that a Chinese-led investment syndicate has agreed to commit up to $107 million in financing through a new investment round. Hong Kong-based investment holding company, O Luxe Holdings Limited, led the investment group, which includes Horizons Ventures, Shanghai Alliance Investment Limited and Altran Technologies. Apple Inc. has recently acquired Canada-based startup Vrvana, maker of the Totem augmented reality headset, TechCrunch reported. Both the companies reportedly declined to confirm news about the deal, which is reportedly worth $30 million. Shares of Thomas Cook Group Plc. were losing around 11 percent in the morning trading in London after the British tour operator reported Wednesday weak UK margins in its fiscal 2017, despite higher group profit and revenues. Further, the company lifted its final dividend, and said it is well-positioned to achieve a full year operating result in line with market expectations..
comments powered by Disqus
Follow RTT